Hong Wang

Contributions to Public Health

• I designed many phase I and phase II clinical trials as the trial statistician, and analyzed data from them. I contributed to these trials by developing and incorporating novel trial designs, and using Bayesian methods to monitor toxicities. In the first paper below, I analyzed data for patients who received fecal microbiota transplant.  I also analyzed data from other clinical studies including retrospective patient data analysis and correlative analysis.
  • Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Zidi B, Zhang S, Badger JH, Vetizou M, Cole AM, Fernandes MR, Prescott S, Costa RGF, Balaji AK, Morgun A, Vujkovic-Cvijin I, Wang H, Borhani AA, Schwartz MB, Dubner HM, Ernst SJ, Rose A, Najjar YG, Belkaid Y, Kirkwood JM, Trinchieri G, Zarour HM. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 Feb 5;371(6529):595-602. doi: 10.1126/science.abf3363. PMID: 33542131; PMCID: PMC8097968. 
  • Shaverdashvili K, Reyes V, Wang H, Mehta D, Marsh C, Waas JK, VanderWeele RA, Peracha SM, Liang H, Socinski MA, Gerber DE, Dowell JE, Villaruz LC. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2. EClinicalMedicine. 2023 Nov 21;66:102317. doi: 10.1016/j.eclinm.2023.102317. PMID: 38192592; PMCID: PMC10772260. 
• I developed statistical analysis methods in survival analysis. In first paper below, I proposed a model, named as the additive inverse Gaussian frailty model, for correlated survival data, and developed a semiparametric estimation procedure in this model. Models and analysis methods in these papers are very useful for the estimation and prediction of patient survival in biomedical studies. In the second paper, multiple comparison procedures were extended to log-rank tests in survival analysis.
  • Wang H, Klein J. Semiparametric estimation for the additive inverse Gaussian frailty model. Communications in Statistics - Theory and Methods. 2012; 41 (12):2269-2278.
  • Logan BR, Wang H, Zhang MJ. Pairwise multiple comparison adjustment in survival analysis. Statistics in Medicine. 2005 Aug; 24 (16):2509-23. PMID: 15977296.
• I have contributed to statistical analysis of pre-clinical in vitro studies, including linear-quadratic and single-hit multi-target models for cell survival curves in clonogenic assays, analysis of long-term bone marrow culture data, gene expression in real-time polymerase chain reaction, complete blood count data, and western blot data.
  • Mukherjee A, Epperly MW, Shields D, Hou W, Fisher R, Hamade D, Wang H, Saiful Huq M, Bao R, Tabib T, Monier D, Watkins S, Calderon M, Greenberger JS. Ionizing irradiation-induced Fgr in senescent cells mediates fibrosis. Cell Death Discov.2021 Nov 12;7(1):349. doi: 10.1038/s41420-021-00741-4. PMID: 34772919; PMCID: PMC8585734.
  • Hamade DF, Epperly MW, Fisher R, Hou W, Shields D, van Pijkeren JP, Leibowitz BJ, Coffman LG, Wang H, Huq MS, Huang Z, Rogers CJ, Vlad AM, Greenberger JS, Mukherjee A. Genetically Engineered Probiotic Limosilactobacillus reuteri Releasing IL-22 (LR-IL-22) Modifies the Tumor Microenvironment, Enabling Irradiation in Ovarian Cancer. Cancers (Basel). 2024 Jan 23;16(3):474. doi: 10.3390/cancers16030474. PMID: 38339228; PMCID: PMC10854600.
• I have also contributed to statistical analysis of preclinical in vivo experiments, including the study of radiation and drug effect on tumor growth, mouse survival under different doses of irradiation and the test of chemicals for radio-protective and radio-mitigative effects, and the study of radiation and drug effect on bone healing. 
  • Epperly MW, Zhang X, Fisher R, Hou W, Franicola D, Shields D, Quickel M, Hankey-Giblin P, Wang H, Greenberger JS. Reduced Competitive Repopulation Capacity of Multipotential Hematopoietic Stem Cells in the Bone Marrow of Friend Virus-infected Fv2-resistant Mice. In Vivo. 2017 May-Jun;31(3):313-320. PubMed PMID: 28438857; PubMed Central PMCID: PMC5461439.
  • Epperly MW, Mukherjee A, Fisher R, Shields D, Hou W, Wang H, Rigatti LH, Green A, Huq MS, Greenberger JS. Chemical Carcinogen (Dimethyl-benzanthracene) Induced Transplantable Cancer in Fanconi Anemia (Fanca-/-) Mice. In Vivo. 2023 Nov-Dec;37(6):2421-2432. doi: 10.21873/invivo.13347. PMID: 37905617; PMCID: PMC10621406.